Eiger BioPharmaceuticals Announces Positive Results in Phase 2

EIGR: Eiger BioPharmaceuticals, Inc.
2018-10-16 16:05:00
Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH)